癌症手术患者围术期药物血栓预防的系统评价与荟萃分析
该系统评价与荟萃分析纳入39项研究,比较癌症手术患者围术期药物血栓预防与无抗凝的相对效果。药物血栓预防组深静脉血栓发生率较低(0.5% vs 1.2%,RR 0.51,95%CI 0.27-0.94;P=0.03),但出血事件发生率显著增高(RR 2.51,95%CI 1.79-3.51;P<0.0001)。肺栓塞发生率和静脉血栓栓塞相关死亡率两组相似。
要点
- 药物血栓预防降低DVT发生率,但显著增加出血事件。
- LMWH较UFH降低DVT发生率(RR 0.81,95%CI 0.66-1.00;P=0.05)。
- 标准延长血栓预防较常规预防显著降低DVT发生率(RR 0.57,95%CI 0.39-0.83;P=0.003)。
核心结论
- 癌症手术患者常规药物血栓预防需谨慎考虑,因虽降低VTE事件但临床显著出血发生率更高。
- 若使用药物血栓预防,术前开始LMWH的延长预防可能是最有效策略。
研究设计与样本
- 系统评价与荟萃分析,检索多个电子数据库至2016年3月31日。
- 纳入39项评估癌症手术患者围术期药物血栓预防相对获益与风险的试验。
- 采用相对风险(RR)及95%置信区间(CI)进行估计。
主要发现
- 药物血栓预防组DVT发生率为0.5%,无预防组为1.2%(RR 0.51,95%CI 0.27-0.94;P=0.03)。
- 药物血栓预防组出血事件发生率显著增高(RR 2.51,95%CI 1.79-3.51;P<0.0001)。
- 肺栓塞发生率两组相似(RR 1.77,95%CI 0.76-4.14;P=0.19)。
- VTE相关死亡率两组相似(1/2,811 vs 2/3,380)。
- LMWH较UFH降低DVT发生率(RR 0.81,95%CI 0.66-1.00;P=0.05)。
临床怎么用
- 癌症手术患者使用药物血栓预防需权衡DVT减少与出血风险增加。
- 若选择药物预防,可考虑术前开始LMWH并延长预防策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the relative effects between pharmacological thromboprophylaxis and no anticoagulation. BACKGROUND: The efficacy and safety of pharmacological thromboprophylaxis in cancer patients undergoing surgery need to be quantified to guide management. METHODS: We searched multiple electronic databases (up to March 31, 2016) for trials of cancer patients undergoing surgery that assessed the relative benefits and harms of perioperative pharmacological thromboprophylaxis. Relative risks (RRs) with 95% confidence intervals (CI) were estimated. RESULTS: A total of 39 studies were enrolled in this review. Patients with pharmacological thromboprophylaxis had a relatively reduced incidence of deep venous thrombosis (DVT) compared with those without (0.5% vs 1.2%, RR 0.51, 95% CI 0.27-0.94; P = 0.03) but a significantly increased incidence of bleeding events (RR 2.51, 95% CI 1.79-3.51; P < 0.0001). The incidence of pulmonary embolism (PE) (RR 1.77, 95% CI 0.76-4.14; P = 0.19) and mortality related to venous thromboembolism (VTE) (1/2,811 vs 2/3,380) were similar between the pharmacological thromboprophylaxis group and the no pharmacological thromboprophylaxis group. Low-molecular-weight heparin (LMWH) reduced the incidence of DVT compared with unfractionated heparin (UFH) (RR 0.81, 95% CI 0.66-1.00; P = 0.05), and standard extended thromboprophylaxis after cancer surgery significant decreased the incidence of DVT as compared with conventional thromboprophylaxis (RR 0.57, 95% CI 0.39-0.83; P = 0.003). CONCLUSIONS: Routine pharmacological thromboprophylaxis for cancer patients undergoing surgery needs to be carefully considered, because although thromboprophylaxis is associated with lower VTE events, there is a higher incidence of clinically significant bleeding events. If pharmacological thromboprophylaxis is to be used, extended thromboprophylaxis started preoperatively with LWMH might be the most effective strategy.
引用
- Guo Q, Huang B, Zhao J, et al. Perioperative Pharmacological Thromboprophylaxis in Patients With Cancer: A Systematic Review and Meta-analysis. Ann Surg. 2017. PMID: 27849664. doi:10.1097/SLA.0000000000002074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。